« Back to Record
Citation APA

Van Wyk, J., Ajana, F., Bisshop, F., De Wit, S., Osiyemi, O., Portilla Sogorb, J., Routy, J.-P., Wyen, C., Ait-Khaled, M., Nascimento, M. C., Pappa, K., Wang, R., Wright, J., Tenorio, A. A., Wynne, B., Aboud, M., Gartland, M., & Smith, K. K. (2020). Efficacy and Safety of Switching to Dolutegravir/Lamivudine Fixed-Dose 2-Drug Regimen vs Continuing a Tenofovir Alafenamide-Based 3-or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living with Human Immunodeficiency Virus Type 1: Phase 3, Randomized, Noninferiority TANGO Study. Clinical infectious diseases, 71(8), 1920-1929. doi:10.1093/cid/ciz1243


Permalink

http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/323655

Van Wyk, J., Ajana, F., Bisshop, F., De Wit, S., Osiyemi, O., Portilla Sogorb, J., Routy, J.-P., Wyen, C., Ait-Khaled, M., Nascimento, M. C., Pappa, K., Wang, R., Wright, J., Tenorio, A. A., Wynne, B., Aboud, M., Gartland, M., & Smith, K. K. (2020). Efficacy and Safety of Switching to Dolutegravir/Lamivudine Fixed-Dose 2-Drug Regimen vs Continuing a Tenofovir Alafenamide-Based 3-or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living with Human Immunodeficiency Virus Type 1: Phase 3, Randomized, Noninferiority TANGO Study. Clinical infectious diseases, 71(8), 1920-1929. doi:10.1093/cid/ciz1243